Diabetes after GLP-1: what are your options?
GLP-1 receptor agonists — semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®) — have changed how Type 2 diabetes and obesity are treated. For some patients, weight loss plateaus, side effects become difficult, cost becomes a barrier, or weight returns after stopping the medication.
Common situations
- Plateaued weight loss despite consistent dosing.
- Side effects that limit dose escalation.
- Long-term cost of weekly injections.
- Weight regain after stopping the medication.
- A1c not at target despite GLP-1 therapy.
What MagnaMetabolic will not do
We do not tell patients to stop their GLP-1 medication. Medication changes should only be made in consultation with your prescribing healthcare professional. GLP-1 medications and metabolic surgery can be complementary tools in a broader treatment plan.
What metabolic surgery may offer
For selected patients with obesity and Type 2 diabetes, metabolic surgery can provide more durable weight loss and glycemic improvement than medications alone. Outcomes depend on patient selection, comorbidities, and ongoing follow-up. Individual results vary.
Next step
A personalized evaluation can help you and your healthcare team understand whether metabolic surgery is appropriate as part of your broader plan.
Ready to begin your metabolic transformation?
Speak with our international care team and receive a personalized plan.